RecruitingNCT06580106

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels

Sponsor

Wake Forest University Health Sciences

Enrollment

50 participants

Start Date

Apr 9, 2025

Study Type

OBSERVATIONAL

Conditions

Leukemia, Myeloid, Acute

Summary

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how a person's genetic makeup affects how they respond to azacitidine and venetoclax, a standard two-drug combination used to treat acute myeloid leukemia (AML). By collecting DNA and tracking treatment outcomes, researchers hope to find genetic markers that predict who benefits most — or who faces worse side effects. **You may be eligible if...** - You are 18 or older - You have been diagnosed with AML (a type of blood cancer) - You are about to start treatment with azacitidine and venetoclax - You can read and understand English **You may NOT be eligible if...** - You have already started AML treatment - You have a serious condition that would make study participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.